Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection

AIDS

Volumn 30, Issue 1, 2016, Pages 93-98

  Grant, Jennifer L ^a   Hawkins, Claudia ^a   Brooks, Hannah ^b   Palella, Frank J ^a   Koppe, Sean W P ^a,c   Abecassis, Michael M ^a   Stosor, Valentina ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

hepatitis C virus infection; liver transplantation; simeprevir; sofosbuvir

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; RALTEGRAVIR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TENOFOVIR; ANTIVIRUS AGENT;

ADULT; ARTICLE; BACKACHE; COHORT ANALYSIS; CONFUSION; FATIGUE; FEMALE; FEVER; GENOTYPE; GRAFT RECIPIENT; GRAFT REJECTION; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTER; TREATMENT DURATION; TREATMENT RESPONSE; ADVERSE DRUG REACTION; COINFECTION; COMPLICATION; FOLLOW UP; LIVER TRANSPLANTATION; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SOFOSBUVIR; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84952941096     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000887     Document Type: Article

References (22)

1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Stock PG, Terrault NA. HIV and liver transplantation: hepatitis C is the last hurdle. Hepatology 2014DOI: 10.1002/hep.27553.
3. Miro JM, Montejo M, Castells L, Rafecas A, Moreno S, Aguero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12:1866-1876.
4. Duclos-Vallee JC, Feray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417.
5. de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983-2993.
6. Terrault NA, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716-726.
7. Campos-Varela I, Peters MG, Terrault NA. Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting. Clin Infect Dis 2015; 60:108-116.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
9. Roland ME, Barin B, Carlson L, Frassetto LA, Terrault NA, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1-and 3-year outcomes. Am J Transplant 2008; 8:355-365.
10. Pissaia A Jr, Borderie D, Bernard D, Scatton O, Calmus Y, Conti F. APRI and FIB-4 scores are useful after liver transplantation independently of etiology. Transplant Proc 2009; 41:679-681.
11. Toniutto P, Fabris C, Bitetto D, Falleti E, Avellini C, Rossi E, et al. Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol Hepatol 2007; 22:1904-1908.
12. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
13. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
14. Del Bello DP, Bichoupan K, Yalamanchili R, Harty A, Ng M, Stivala A, et al. Real-world data on HIV positive patients with HCV genotype 1, 2 and 3 on sofosbuvir-and simeprevircontaining regimens. [Abstract 994]. Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7-11 November 2014; Boston, Massachusetts.
15. Grant J, Stosor V, Palella F, Green R, Thomas G, McGregor D, et al. Successful treatment with direct acting antivirals in HIV/ HCV patients. [Abstract 694]. 22nd Conference on Retroviruses and Opportunistic Infections; 23-26 February 2015; Seattle, Washington.
16. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371:2375-2382.
17. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Serif T, et al. Ledipasvir-sofosbuvir with ribavirin for the treatment of HCV in patients with posttransplant recurrence: preliminary results of a prospective, multicenter study. [Abstract 8]. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7-11 November 2014; Boston, Massachusetts.
18. Brown RS, Reddy K, O'Leary JG, Kuo A, Morelli G, Stravitz R, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCVTARGET longitudinal, observational Study. [Abstract LB-4]. Program and Abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7-11 November 2014; Boston, Massachusetts.
19. Pungpapong S, Werner KT, Aqel B, Leise MD, Murphy JL, Henry TM, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. [Abstract 9]. Program and Abstracts of the 65th AnnualMeeting of theAmerican Association for the Study of Liver Diseases; 7-11 November 2014; Boston, Massachusetts.
20. Campos-Varela I, Straley S, Agudelo EZ, Carlson L, Terrault NA. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients. Liver Transpl 2015; 21:272-274.
21. Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015; 60:1031-1035.
22. Kwo P, Gitlin N, Nahas R, Bernstein D, Rojter S, Schiff E, et al. A Phase 3, randomised, open-label study to evaluate the efficacy and safety of 12 and 8 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and-experienced patients with chronic HCV genotype 1 infection without cirrhosis: OPTIMIST-1. [Abstract LP14]. European Association for the Study of the Liver (EASL) 50th International Liver Congress (ILC); 22-26 April 2015; Vienna, Austria.